anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Secondary use of data for research purposes is especially important in rare diseases (RD), since, per definition, data are sparse. The European Joint Programme on Rare Diseases (EJP RD) aims at developing an RD infrastructure which supports the secondary use of data. Significant amounts of RD data are a) distributed and b) available only in pseudonymised format. Privacy-Preserving Record Linkage (PPRL) concerns the linking of such distributed datasets without disclosing the participant's identities. We present a concept for linking a PPRL Service to the EJP RD Virtual Platform (VP). Level 1 (resource discovery) connection is provided by running an FDP within the PPRL Service. On Level 2 (data discoverability), the PPRL Service can represent both, an individual and a catalog endpoint. Our solution can count patients in PPRL-supporting resources, count duplicates only once, and count only patients registered to multiple resources. Currently, we are preparing the deployment within the EJP RD VP.
The necessity of biliary drainage before pancreaticoduodenectomy remains controversial in cases involving malignant obstructive jaundice; however, the benefits of biliary drainage have been reported in cases with severe hyperbilirubinemia. Herein, we present the case of a 61-year-old man suffering from jaundice due to distal cholangiocarcinoma. In this case, obstructive jaundice was refractory to repeat endoscopic drainage and bilirubin adsorption. Hyperbilirubinemia persisted despite successful implementation of biliary endoscopic sphincterotomy and two rounds of plastic stent placements. Stent occlusion and migration were unlikely and oral cholagogues proved ineffective. Owing to the patient's surgical candidacy and his aversion to nasobiliary drainage due to discomfort, bilirubin adsorption was introduced as an alternative therapeutic intervention. Following repeated adsorption sessions, a gradual decline in serum total bilirubin levels was observed and pancreaticoduodenectomy was scheduled. The patient successfully underwent pancreaticoduodenectomy with portal vein resection and reconstruction and D2 lymph node dissection. After the surgery, the serum bilirubin levels gradually decreased and the patient remained alive, with no recurrence at 26 months postoperatively. Therefore, this case highlights the feasibility and safety of performing pancreaticoduodenectomy in patients with severe, refractory jaundice who have not responded to repeated endoscopic interventions and have partially responded to bilirubin adsorption.
The experimental group was given training on infancy vaccines and breastfeeding. The times of the trainings are determined based on the Postpartum Care Management Guide of the Ministry of Health. In the hospital on the first day after birth, 2-7. days and 30-42. Three days in total, trainings were given on breastfeeding and childhood vaccinations by making home visits. The training content has been prepared by taking into account the Ministry of Health Breastfeeding Guide (5) and the Ministry of Health's vaccination calendar and the Primary Care Vaccine Guide. The trainings will be given to the puerperant women individually. About 30 minutes of training will be given and their questions, if any, will be answered.
Objective: To develop a simple screening questionnaire for persistent postural-perceptual dizziness (PPPD) and evaluate its screening ability. Methods: A convenience sample of 296 individuals who met the inclusion criteria between November 2021 and January 2023 were prospectively selected for three rounds of screening at the Vertigo Specialty Clinic of the Department of Otorhinolaryngology-Head and Neck Surgery in the First Hospital of Shanxi Medical University. In conjunction with expert opinion and statistical analysis, the first and second rounds of screening were used to modify and finalize the questionnaire entries, and the third round of screening was used to evaluate the questionnaire's screening ability. Independent sample t-test was used for inter group comparison, reliability and validity indicators were employed to screen and evaluate questionnaire entries, and the receiver operating characteristic (ROC) curve was plotted to determine the optimal cut-off value and corresponding sensitivity and specificity. Results: The final PPPD screening questionnaire entries included 21 items. In evaluating the reliability of this questionnaire, the Cronbach's alpha coefficient was 0.831, the half folding coefficient was 0.742, the content validity was 0.86, and the Kaiser-Meyer-Olkin (KMO) value in the structural validity was 0.811. Additionally, there were six factors with characteristic root>1 and a cumulative contribution rate of 62.62%. The area under the ROC curve of the screening questionnaire was 0.935 (95%CI: 0.877-0.992), and the optimal cut-off value was 8.5, with a sensitivity of 85.0%, a specificity of 85.5%, and a Kappa value of 0.653. Conclusion: The PPPD simple screening questionnaire designed in this study has a high sensitivity and specificity, making it a useful tool for identifying PPPD patients.
Periodontitis is a chronic infectious disease that affects the oral health of adults. Periodontal stem cells (PDLSCs) have good self-renewal and multipotential differentiation abilities to maintain the integrity of periodontal support structure and repair defects. This study aimed to elucidate the role of peroxisome proliferator activated receptor-γ co-activator 1-α (PGC-1α) in lipopolysaccharide (LPS)-induced PDLSCs and the underlying mechanisms related to predicated that pyrin domain (PYD)-only protein 1 (POP1). Notably downregulated PGC-1α and POP1 expression was observed in LPS-induced PDLSCs. PGC-1α or POP1 overexpression significantly reduced the inflammation and enhanced the osteogenic differentiation of LPS-treated PDLSCs. Particularly, PGC-1 bound to POP1 promoter region and upregulated POP1 expression. Moreover, POP1 knockdown ameliorated the impacts of PGC-1α overexpression on the inflammation and osteogenic differentiation in LPS-induced PDLSCs. Besides, PGC-1α inactivated NLRP3 signaling in LPS-treated PDLSCs, which was reversed by POP1 knockdown. Taken together, PGC-1α inhibits NLRP3 signaling through transcriptional activation of POP1, thereby alleviating inflammation and strengthening osteogenic differentiation of LPS-induced PDLSCs.
Fundus neovascularization diseases are a series of blinding eye diseases that seriously impair vision worldwide. Currently, the means of treating these diseases in clinical practice are continuously evolving and have rapidly revolutionized treatment opinions. However, key issues such as inadequate treatment effectiveness, high rates of recurrence, and poor patient compliance still need to be urgently addressed. Multifunctional nanomedicine can specifically respond to both endogenous and exogenous microenvironments, effectively deliver drugs to specific targets and participate in activities such as biological imaging and the detection of small molecules. Nano-in-micro (NIM) delivery systems such as metal, metal oxide and up-conversion nanoparticles (NPs), quantum dots, and carbon materials, have shown certain advantages in overcoming the presence of physiological barriers within the eyeball and are widely used in the treatment of ophthalmic diseases. Few studies, however, have evaluated the efficacy of NIM delivery systems in treating fundus neovascular diseases (FNDs). The present study describes the main clinical treatment strategies and the adverse events associated with the treatment of FNDs with NIM delivery systems and summarizes the anatomical obstacles that must be overcome. In this review, we wish to highlight the principle of intraocular microenvironment normalization, aiming to provide a more rational approach for designing new NIM delivery systems to treat specific FNDs.
Human antibody preparations enriched for antibodies that bind to human T-cell receptor peptide or conformational determinants are disclosed. Also disclosed are methods for making such antibody preparations from human plasma Cohn fractions by immunoaffinity purification using either recombinant Tcr protein or Tcr variable region peptides. Purification of Tcr antibodies from human or animal antibody mixtures is accomplished by immunoaffinity procedures using recombinant human T-cell receptor proteins. The affinity purified antibodies can bind to intact membrane-bound Tcr using fluorescence activated cell sorting (FACS) and can inhibit T-cell proliferation following stimulation by mitogen. Affinity purified human polyclonal antibodies can inhibit lytic activity of natural killer cells on a monoclonal T-cell line. The antibody preparations can be used for diagnosis, monitoring and therapy of various autoimmune-related syndromes.
The invention provides mesalazine dripping pills and a preparation method thereof. According to the invention, mesalazine and a substrate are combined according to a weight ratio of 1:1-100, such that the dripping pills are obtained. According to the invention, a mesalazine preparation form is changed from tablets unto dripping pills, such that the medicine is dispersed into the substrate in a state of molecules, colloid or microcrystalline. Medicine total surface area is increased. The substrate is hydrophilic, such that a wetting effect is provided for the medicine, and the medicine can be rapidly dispersed into micro-particles or solution. Therefore, medicine dissolving and absorption are accelerated, and bioavailability and medicine stability are improved. The dripping pills are highly efficient and convenient. Therefore, the mesalazine dripping pills provided by the invention has the advantages of accelerated dissolving and absorption, convenient application, high bioavailability and medicine stability, reduced adverse reaction, fast effect, convenient carrying, simple production process, and suitability for large-scale productions.
Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
Participants in this group will be required to write once weekly for 4 consecutive weeks. Participants will be instructed to write objectively about what they did the day prior and to avoid writing about their emotions or opinions. The participant will be required to write in their preferred language (English or Spanish).
BACKGROUND: Subscapularis function is critical after anatomic total shoulder arthroplasty (aTSA). Recently, however, a technique has been described that features a chevron or V-shaped subscapularis tendon cut (VT). This biomechanical study compared repair of the standard tenotomy (ST), made perpendicular to the subscapularis fibers, to repair of the novel VT using cyclic displacement, creep, construct stiffness, and load to failure.
METHODS: This biomechanical study used 6 pairs of fresh frozen paired cadaveric shoulder specimens. One specimen per each pair underwent VT, the other ST. Subscapularis tenotomy was performed 1 cm from the insertion onto the lesser tuberosity. For VT, the apex of the V was 3 cm from the lesser tuberosity. After tenotomy, each humerus underwent humeral head arthroplasty. Eight figure-of-8 sutures were used to repair the tenotomy (Ethibond Excel; Ethicon, US LLC). Specimens were cyclically loaded from 2 to 100 N at 45 degrees abduction at a rate of 1 Hz for 3000 cycles. Cyclic displacement, creep, and stiffness and load to failure were measured.
RESULTS: Cyclic displacement did not differ significantly between the ST and VT from 1 to 3000 cycles. The difference in displacement between the V-shaped and standard tenotomy at 3000 cycles was 1.57 mm (3.66 ± 1.55 mm vs. 5.1 ± 2.8 mm, P = .31, respectively). At no point was the V-shape tenotomy (VT) >3 mm of average displacement, whereas the standard tenotomy (ST) averaged 3 mm of displacement after 3 cycles. Creep was significantly lower for VT in cycles 1 through 3. For all cycles, stiffness was not significantly different in the VT group compared with the ST group. Load to failure was not statistically significant in the VT compared to the standard tenotomy throughout all cycles (253.2 ± 27.7 N vs. 213.3 ± 76.04 N; P = .25, respectively). The range of load to failure varied from 100 to 301 N for standard tenotomy compared with 216 to 308 N for VT.
CONCLUSION: This study showed that VT and ST demonstrated equivalent stiffness, displacement, and load to failure. VT had the benefit of less creep throughout the first 3 cycles, although there was no difference from cycle 4 to 3000. The VT had equivalent biomechanical properties to the ST at time zero, an important first step in our understanding of the technique. The VT technique warrants further clinical study to determine if the technique has clinical benefits over ST following aTSA.
Children in neuronal cognition treatment group will experienced neural cognition training 30min each day for 3 months. ASD children are followed up closely.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other rimabotulinumtoxinB products may be misleading.

Cervical Dystonia

A two-stage assay was used to test for immunogenicity and neutralizing activity induced by treatment with MYOBLOC. In order to account for varying lengths of follow-up, life-table analysis methods were used to estimate the rates of development of immune responses and neutralizing activity. During the repeated treatment studies, 446 subjects were followed with periodic ELISA based evaluations for development of antibody responses against MYOBLOC. Only patients who showed a positive ELISA assay were subsequently tested for the presence of neutralizing activity against MYOBLOC in the mouse neutralization assay (MNA). 12% of patients had positive ELISA assays at baseline. Patients began to develop new ELISA responses after a single treatment session with MYOBLOC. By six months after initiating treatment, estimates for ELISA positive rate were 20%, which continued to rise to 36% at one year and 50% positive ELISA status at 18 months. Serum neutralizing activity was primarily not seen in patients until after 6 months. Estimated rates of development were 10% at one year and 18% at 18 months in the overall group of patients, based on analysis of samples from ELISA positive individuals. The effect of conversion to ELISA or MNA positive status on efficacy was not evaluated in these studies, and the clinical significance of development of antibodies has not been determined.

The data reflect the percentage of patients whose test results were considered positive for antibodies to MYOBLOC in both an in vitro and in vivo assay. The results of these antibody tests are highly dependent on the sensitivity and specificity of the assays. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors including sample handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to MYOBLOC with the incidence of antibodies to other products may be misleading. 

Chronic Sialorrhea

Immunogenicity potential was not further evaluated for MYOBLOC in the treatment of chronic sialorrhea.
The internal consistency reliability was determined by calculating Cronbach's alpha (n=300). Intraclass correlation coefficients (ICCs) were calculated for test-retest reliability (n=67). Construct validity was determined by comparing with the Venham Picture Test (VPT). The factor structure was examined using exploratory factor analysis (EFA). Confirmatory factor analysis (CFA) was used for the dimensionality. The cut-off points of the Turkish version of MCDASf were plotted using a receiver operating characteristic (ROC) curve.
The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
A nutritional supplement for providing, and for promoting the health of salivary glands and/or supporting normal or healthy swallowing includes ingredients obtainable from turmeric, ginger, and horseradish. The nutritional supplement may also be used to treat symptoms such as symptoms of a common cold, sore throat, congestion, mucositis, laryngitis, mucous membrane inflammation and sialorrhea, as well as inflammation and viral infectin, or to inhibit or exterminate a virus. This nutritional supplement can be orally administered a person. The nutritional supplement may further include optional ingredients such as ingredients obtainable from slippery elm bark powder and green tea, as well as other optional ingredients. This nutritional supplement may further include a pharmaceutically acceptable carrier for oral administration.  
     Also disclosed are methods of providing nutrition, for promoting the health of salivary glands and/or supporting normal or healthy swallowing, as well as methods for treating symptoms of a common cold, sore throat, congestion, mucositis, laryngitis, mucous membrane inflammation and sialorrhea. Methods of treating inflammation, and viral infections, as well as inhibiting or exterminating viruses are also disclosed.
Aqueous dispersions of acicular fine particle size titanium dioxide contain 20 to 60% by weight solids plus a polycarboxylic acid dispersant and are used e.g. in the preparation of sun screens. The dispersions are transparent to visible light and absorbent to UV light of broad spectrum. Usually the titanium dioxide has a largest dimension within the range 0.01 to 0.15 micron. The dispersions are produced by milling e.g. in a high speed mill, until the required UV absorbancy is attained.
IV infusion AV-380. This cohort will proceed at a new dose level with approval of the Dose Escalation Committee, after evaluation of data from the previous cohort. IV infusion AV-380. 7 doses will be given -- the 2nd dose will be 28 days after the first dose, the remaining 5 doses will be given every 2 weeks.
Strong CYP3A4 inhibitors: The risk of myopathy is increased by reducing the elimination of the simvastatin component of VYTORIN. Hence when VYTORIN is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity increases the risk of myopathy and rhabdomyolysis, particularly with higher doses of VYTORIN. [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).] Concomitant use of drugs labeled as having a strong inhibitory effect on CYP3A4 is contraindicated [see Contraindications (4)].  If treatment with itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with VYTORIN must be suspended during the course of treatment.

Although not studied clinically, voriconazole has been shown to inhibit lovastatin metabolism in vitro (human liver microsomes). Therefore, voriconazole is likely to increase the plasma concentration of simvastatin. It is recommended that dose adjustment of VYTORIN be considered during concomitant use of voriconazole and VYTORIN to reduce the risk of myopathy, including rhabdomyolysis. [see Warnings and Precautions (5.1)].

Cyclosporine or Danazol: The risk of myopathy, including rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol. Therefore, concomitant use of these drugs is contraindicated. [see Contraindications (4), Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention describes new derivatives of quinoxalinedione of the formula (I)   where values R 1 , R 5 -R 8  are given in p. 1 of the invention claim. Compounds show an affinity to AMPA-receptors. Also, invention describes a method of their synthesis and a pharmaceutical agent based on said. EFFECT: new compounds indicated above, valuable pharmacological property. 6 cl
This is a single center phase I/II study that is designed to assess the safety and efficacy of splenic artery embolization in the setting of symptomatic portal hypertension. All participating investigators have signed the protocol agreement and no investigator will be added until they sign the agreement. The study will not be initiated until FDA and IRB approval is obtained.

The study will consist of a 4 week screening period, day of treatment, and 12-month follow-up period. 60 subjects will be enrolled, with a goal of randomizing 30, at the University of Minnesota Medical Center. Enrollment is expected to take up to 48 months. The collection of data will be accomplished by utilizing a clinical research team that will obtain symptomatic portal hypertension improvement and safety assessments. Efficacy assessments will include; change in portal vein velocity, ascitic fluid production change, reduction in splenic size, and improvement in quality of life (QoL). Safety assessments include subject and investigator reported adverse events, subjective pain, and splenic abscess formation.
Bioadhesives and controlled release drug delivery systems were prepared from a series of starches grafted with acrylic monomers by two initiation methods: chemical and radiation. In general, the grafted starches prepared by chemical initiation with a Ce4+/Ce3+ redox system showed a lower bioadhesion and released the model drugs in relatively shorter. These materials can be characterized by measuring their swelling in water and at various pH values and the molecular weight of the branched acrylic polymer grafted onto the starch can also be determined. Bioadhesives and controlled release drug delivery systems were also prepared from a series of starches from various sources grafted with acrylic acid by radiation with 60Co. These materials had better bioadhesive and controlled drug release properties. The effect of mono- and divalent cations present in the graft copolymers indicated a particularly high potential as bioadhesive materials for oral drug delivery systems.
FIELD: veterinary microbiology. SUBSTANCE: vaccine has adsorbed complex water soluble antigens extracted from microbial cells of strain Fusobacterium necrophorum H-89-5 and H-89-29 DEP NIISX of I and II serotypes. Extraction is carried out with enzyme which destroys cell envelope. Strains were grown separately, biomass is separated from cultural fluid, microbial cells were disrupted, antigens were optimized by microbial protein content, mixed with equal volumes (by protein) and adsorbed. Microbial cells were disrupted by enzyme action in aqueous medium, centrifuged, supernatant is inactivated with formalin and diluted with distilled water. To prepared complex water soluble antigens 30% aluminium hydroxide (3% solution) is added at the following ratio of components per 1 l vaccine, vol. complex water soluble antigen of Fusobacterium necrophorum of I serotype 30-40; complex water soluble antigen of Fusobacterium necrophorum of II serotype 30-40; formalin 0.3-0.4, and aluminium hydroxide (3% solution) 25-30. EFFECT: improved method of vaccine preparing.